Ignite Creation Date:
2025-12-24 @ 7:44 PM
Ignite Modification Date:
2025-12-29 @ 9:08 PM
Study NCT ID:
NCT05590403
Status:
COMPLETED
Last Update Posted:
2025-03-06
First Post:
2022-10-18
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and Above
Sponsor:
GlaxoSmithKline
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-10-28
Start Date Type:
ACTUAL
Primary Completion Date:
2023-03-13
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-02-12
Completion Date Type:
ACTUAL
First Submit Date:
2022-10-18
First Submit QC Date:
None
Study First Post Date:
2022-10-21
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2024-03-13
Results First Submit QC Date:
None
Results First Post Date:
2024-05-21
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-02-11
Last Update Post Date:
2025-03-06
Last Update Post Date Type:
ACTUAL